Vascular Solutions (VASC) 35.31 $VASC Best Performing

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 11:47 AM

Vascular Solutions (VASC) 35.31 $VASC

Best Performing Stocks On Earnings
Bespoke Investment Group - at Seeking Alpha - Sun Apr 26, 3:00AM CDT
The average stock that has reported this season has gained 0.71% on its earnings reaction day (the first trading day following its report). Below is a list of the stocks that have done the best on their earnings reaction days. As shown, Travelzoo...
TZOO: 12.89 (-0.14), ASPS: 23.24 (+0.76), SKX: 89.66 (+2.79), SXC: 17.43 (-0.09), HSTM: 31.02 (+0.88), ZEP: 19.88 (-0.03), SQNS: 2.10 (-0.15), TTS: 14.01 (-0.17), GIMO: 29.75 (+6.16), DCO: 32.10 (+1.06), PIR: 13.29 (+0.23), APOG: 53.48 (+0.55), CNMD: 53.40 (-0.83), DPZ: 113.96 (+4.73), PGI: 10.79 (+1.29), TCPI: 3.86 (-0.07), VASC: 35.31 (+0.45), AAN: 32.80 (+3.43), MSFT: 47.87 (+4.53), AMZN: 445.10 (+55.11), HAS: 71.61 (-0.10), ATI: 34.61 (+0.05), ECHO: 32.68 (-1.14), ACTG: 11.10 (+1.08), MDSO: 57.59 (+0.05), CAMP: 20.34 (-1.41), HA: 23.60 (+2.10), RMBS: 13.99 (-0.31), CLB: 124.69 (-0.63), ADPT: 63.78 (+2.13), NFLX: 558.40 (-0.66), TBI: 29.20 (+4.39), RS: 63.14 (+0.45), CE: 65.85 (+0.75), CPHD: 58.97 (+5.67), CLGX: 39.45 (+0.23), WIRE: 45.34 (+3.93), BAS: 8.70 (+0.62), FTNT: 38.68 (-0.04), EHTH: 13.50 (+2.06)

Mead Johnson (MJN) Tops Q1 Earnings, Sales Miss the Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 3:36PM CDT
Mead Johnson (MJN) posted mixed financial results in the first quarter of 2015, with bottom line exceeding the Zacks Consensus Estimate and the top line missing the same
SRDX: 26.53 (+0.03), MJN: 97.94 (+1.53), LMAT: 8.60 (+0.03), VASC: 35.31 (+0.45)

Nasdaq stocks posting largest percentage increases
AP - Thu Apr 23, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMSC: 6.88 (-3.12), VCYT: 9.63 (+0.40), ASPS: 23.24 (+0.76), OFLX: 29.59 (+0.39), SCYX: 9.47 (-0.52), ANGI: 6.16 (-0.24), VASC: 35.31 (+0.45), PKT: 11.43 (-0.02), GLUU: 5.45 (+0.09), ASML: 107.16 (-1.53), DWCH: 7.76 (-0.34)

22.0% Return Seen to Date on SmarTrend Vascular Solutions Call (VASC)
Comtex SmarTrend(R) - Thu Apr 23, 9:20AM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on December 4th, 2014 at $27.12. In approximately 5 months, Vascular Solutions has returned 22.01% as of today's recent price of $33.09.
VASC: 35.31 (+0.45)

Vascular Solutions raises fiscal 2015 guidance after Q1 results
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:20AM CDT

VASC: 35.31 (+0.45)

Vascular Solutions' (VASC) CEO Howard Root on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Apr 21, 8:32PM CDT

VASC: 35.31 (+0.45)

Vascular Solutions posts 1Q profit
Automated Insights - Tue Apr 21, 3:51PM CDT
MINNEAPOLIS (AP) _ Vascular Solutions Inc. (VASC) on Tuesday reported first-quarter earnings of $2.2 million.
VASC: 35.31 (+0.45)

Vascular Solutions (VASC) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Apr 21, 3:25PM CDT

VASC: 35.31 (+0.45)

Vascular Solutions beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 3:06PM CDT

VASC: 35.31 (+0.45)

Vascular Solutions Reports First Quarter Results
GlobeNewswire - Tue Apr 21, 3:05PM CDT
- Revenue increased 16% to $34.6 million, exceeding the top end of guidance
VASC: 35.31 (+0.45)

Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 4:35PM CDT

EWBC: 41.11 (-0.54), SMCI: 30.44 (-0.79), VMW: 88.23 (-0.86), NBR: 15.04 (-0.53), ZIXI: 4.55 (+0.12), ILMN: 189.59 (-3.01), MANH: 54.90 (+0.08), YHOO: 44.52 (+0.83), DFS: 58.39 (-0.28), ACE: 108.51 (+0.20), CMG: 637.50 (+1.90), VASC: 35.31 (+0.45), FTI: 40.01 (-1.41), IRBT: 34.19 (+0.10), ADTN: 15.98 (-0.03), YUM: 87.10 (+3.03), CREE: 31.87 (-0.36), INFN: 20.15 (+0.81), SYK: 96.90 (-0.28), URI: 96.64 (-1.89), IBKR: 34.49 (+0.29), CAMP: 20.34 (-1.41), BRCM: 44.46 (-0.98), AMGN: 167.91 (-1.26), HTS: 18.55 (+0.04), ISRG: 505.92 (-6.85), DLB: 40.61 (-0.65), PFPT: 54.33 (-2.60), FULT: 12.09 (-0.11)

MedIntelliBase Lower Limb Critical Limb Ischemia Therapeutics MarketTracksTM ("CLI-LL MarketTracks"

M2 - Mon Apr 20, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fgkmfx/medintellibase) has announced the addition of the "MedIntelliBase? Lower Limb Critical Limb Ischemia Therapeutics MarketTracksTM ("CLI-LL MarketTracks"

" subscription to their offering. Medical industry executives who rely on timely business intelligence now have two smarter alternatives - MedIntelliBase Alerts and MedIntelliBase MarketTracks services. Both cloud and mobile, fully searchable services help biotech, medical device and pharmaceutical companies gain and sustain their competitive advantage. MedIntelliBase gives you customized cloud and mobile intelligence services to satisfy your highly specialized information collection and reporting needs. Highly customized, precisely targeted intelligence on areas of business, finance, regulations, clinical research and medical technology interest are pushed, streamed and accessed as you require. In particular, MedIntelliBase (MIB) MarketTracks are concise Summaries of Clinical Trials and Product Technologies. All Clinical Trial Summaries are indexed by Company, Principal Investigator (PI) and PI Study Site. All Product Technology Summaries are indexed by Company. The Summaries are updated throughout the month published in final form each month with Summary Update Emails sent to you and RSS Breaking News fed to you. For the Subject Area ""Lower Limb ""Critical Limb Ischemia (CLI) Therapeutics - MarketTracks: As of January 2015 the Number of Clinical Trials/Registries included = 45; the Number of Product Technologies included = 25; the Number of Companies included = 22. This Subject Area is growing as its authors discover newly announced trials and emerging product technologies. Key Topics Covered: 1. Arteries 2. Therapeutic Approach 3. Clinical Focus 4. Companies Companies Mentioned - Abbott Vascular Devices - AtheroMed, Inc. - Bard Peripheral Vascular, Inc. / C. R. Bard - BIOTRONIK - Boston Scientific Corporation, Inc. - Cardiovascular Systems, Inc. - Cook, Inc. - Covidien (eV3) - CryoVascular Systems, Inc. (Boston Scientific Corporation) - Edwards Lifesciences - EKOS Corporation - Guidant Corporation (Abbott Vascular Devices/Boston Scientific Corporation) - Intact Vascular, Inc. - Invatec (Medtronic) - Lutonix, Inc. - Medtronic (Bayer / MEDRAD Interventional (Possis Medical, Inc.)) - Medtronic Vascular - Spectranetics Corporation - TriReme Medical - Terumo Medical Corporation - Vascular Solutions, Inc. For more information visit http://www.researchandmarkets.com/research/fg...ntellibase
BSX: 18.34 (-0.08), SPNC: 26.52 (-8.18), MDT: 77.61 (-0.89), CSII: 37.22 (-2.00), EW: 138.33 (-3.59), VASC: 35.31 (+0.45)

Shares of VASC Up 13.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 08, 10:08AM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on December 4th, 2014 at $27.12. In approximately 4 months, Vascular Solutions has returned 13.68% as of today's recent price of $30.83.
VASC: 35.31 (+0.45)

Vascular Solutions, Inc. to Webcast First Quarter Conference Call
GlobeNewswire - Tue Mar 31, 3:05PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it will host a live webcast of its first quarter conference call on Tuesday, April 21 at 3:30pm CDT. Vascular Solutions' Chief Executive Officer, Howard Root, Chief Financial Officer, James Hennen, and VP of Corporate Development, Phil Nalbone, will discuss the company's first quarter results. The company will issue an earnings news release after market close on Tuesday, April 21.
VASC: 35.31 (+0.45)

Vascular Solutions Shares Up 14.0% Since SmarTrend's Buy Recommendation (VASC)
Comtex SmarTrend(R) - Wed Mar 25, 11:44AM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on December 4th, 2014 at $27.12. In approximately 4 months, Vascular Solutions has returned 14.01% as of today's recent price of $30.92.
VASC: 35.31 (+0.45)

Vascular Solutions Launches PolarCath(TM) Peripheral Dilatation System
GlobeNewswire - Mon Mar 16, 8:00AM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it has commenced sales of the PolarCath peripheral dilatation system in the United States in collaboration with NuCryo Vascular LLC, the manufacturer of the product.
VASC: 35.31 (+0.45)

Medtronic Positive on Covidien Integration, Potential Synergy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 1:30PM CST
On Mar 4, 2015, we issued an updated research report on Medtronic, Inc. (MDT).
CSII: 37.22 (-2.00), MDT: 77.61 (-0.89), ABAX: 63.62 (+0.31), VASC: 35.31 (+0.45)

Bioscrip Q4 Loss Wider than Expected, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:30AM CST
BioScrip, Inc. (BIOS) recently declared its fourth-quarter 2014 results.
CSII: 37.22 (-2.00), ABAX: 63.62 (+0.31), BIOS: 5.26 (+0.01), VASC: 35.31 (+0.45)

Insider Trading Alert - VASC, EA And FFIV Traded By Insiders
at The Street - Mon Mar 02, 11:16AM CST
Stocks with insider trader activity include VASC, EA and FFIV
EA: 59.89 (+0.01), FFIV: 123.18 (+0.78), VASC: 35.31 (+0.45)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Instanodes Tackling Quantum Threats in Blockchain

Diving Into Quantum Cryptography for Blockchain Instanodes is throwing down the gauntlet for the blockchain crowd as the field of quantum computing edges ever closer to unsettling the cryptographic order. This company's latest play? Post-quantum account engineering for major players like Ethereum and Solana. And it's not just tinkering—they're giving the status quo a...

Envision's Green Ammonia Powers Game-Changing Shipping Milestone

Envision's Big Bet on Green Ammonia It's a day to talk about paradigms shifting on the high seas. Envision, a heavy hitter in the green tech arena, just fueled the very first Very Large Ammonia Carrier (VLAC) with their certified green ammonia. Now, that's not just a milestone, it’s like finding a four-leaf clover in the world of maritime decarbonization—a tough nut...

i-80 Gold's Q3 2026: Production Plans Unveiled

Gold Miners on the Move: Eye on i-80 Wake up and smell the gold, folks. i-80 Gold is ramping up to increase its yearly gold production targets, aiming for a hefty 150,000 to 200,000 ounces by 2028. Now, if you’ve been around the block like me, you know these are the kind of numbers that get investors either shifting in their chairs or springing to their feet. A Brief...

ACA 2027 Enrollment: New Rules Aim to Simplify Coverage

Navigating New Waters in 2027 ACA Open Enrollment If you're one of those folks who likes to wait until the last minute, the ACA's got a wake-up call for you this year. The 2027 open enrollment period started on November 1, 2026, with some pretty notable changes. The deadline for coverage beginning January 1, 2027, is December 15, so don't take a nap on this one, alright?...

HARIBO Unveils Five Boldly Colored Gummies

By Ryan Hughes Updated Nov 2, 2026 Category News Views 239

HARIBO's New Fruity Lineup: A Sweet Adventure Hey folks, grab a bag of these new HARIBO gummies, and you're in for a fruity ride. The candy maker's got a new trick up its sleeve with five whimsical, boldly colored gummies. They've dubbed these little treats single-flavor goodies—each with one distinct shape and taste. It's a marketing move that screams 'collect them...

D-Wave Faces Securities Fraud Class Action: Details Inside

D-Wave Quantum Inc. in Hot Water Well folks, looks like D-Wave Quantum Inc. (NASDAQ: QBTS) is knee-deep in a securities fraud class action lawsuit. This ain't just another day in the quantum computing trenches. We've got Kessler Topaz Meltzer & Check, LLP, a big player in securities litigation, rallying the troops here—a clear sign that this case is packing some hefty...

Oracle's $20 Billion Offering: What Investors Need to Know

Oracle's Big Play: A $20 Billion Offering Nobody said playing in the big leagues was easy, and Oracle seems to be doubling down on that idea. Today, they spilled the beans on their ambition to rake in a cool $20 billion through an offering of common stock and senior notes. For those of us who keep a close eye on NYSE:ORCL, this is more than just a number—it's a signal...

New Study Exposes Grim Reality for Moderate Aortic Stenosis

Uncovering the Stark Truth of Moderate Aortic Stenosis When you hear about heart issues, the last thing you want to think about is moderate anything. But this study out of San Diego sure throws a wrench in how we size up moderate aortic stenosis. Turns out these patients aren't just in a holding pattern—they're facing some serious storm clouds. High Stakes for...

XPENG Eyes South Korea Entry with Industry Veteran

A Veteran's Task in a New Territory Piling onto its international ambitions, XPENG has roped in Lee Man-sik, a seasoned auto industry professional, to break into South Korea. South Korea isn’t just another market—it’s one of the toughest stages for the automotive industry. The customers there are sharp, with a keen eye for tech and quality. So XPENG, trading under...

Andrea P. Davis: A Leadership Luminary Honored

A Decade-Spanning Influence in Leadership After years of helping executives navigate the twists and turns of organizational life, Andrea P. Davis stands out as The Inner Circle's Pinnacle Professional of the Year. With over 25 years under her belt, Davis has tackled strategic planning, brand development, and organizational transformation like a prizefighter in the ring....